Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duloxetine + pregabalin
- Development stage
- Unknown
- Lead developer
- Shamir Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of duloxetine and pregabalin refers to a pharmacological treatment regimen utilized as an active control arm in clinical research conducted by the Assaf-Harofeh Medical Center, specifically for the treatment of fibromyalgia induced by emotional trauma. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that modulates descending inhibitory pain pathways by increasing the synaptic availability of serotonin and norepinephrine. Pregabalin is a gabapentinoid that binds to the alpha-2-delta subunit of voltage-gated calcium channels, thereby reducing the calcium-dependent release of excitatory neurotransmitters such as glutamate and substance P. In the specific trial context (NCT04157127), this pharmaceutical intervention is compared against hyperbaric oxygen therapy (HBOT) to evaluate its impact on fibromyalgia symptoms, quality of life, and neuroplasticity as observed through SPECT imaging.
- Brand names
- CymbaltaLyrica
- Other names
- duloxetinepregabalinduloxetine + pregabalin-Assaf-Harofeh Medical Center
02
Targets
SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on duloxetine + pregabalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duloxetine + pregabalin.